| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.08 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.09 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.29 | 0.09 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.28 | 0.09 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.054 | 0.09 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.1 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |